Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi) therapeutics for the treatment of rare genetic, cardio-metabolic, and hepatic infectious diseases. The company was founded in 2002 and has since focused on advancing RNAi-based drugs to address unmet medical needs. Alnylam has several drugs in various stages of development, targeting diseases such as hereditary amyloidosis, acute hepatic porphyrias, and primary hyperoxaluria. They are known for their innovative work in utilizing RNAi technology to silence disease-causing genes and have garnered attention for their potential to revolutionize the treatment of genetic disorders.